News

Under this partnership, BioLeap and Jubilant will integrate BioLeap’s computational fragment based drug design platform with Jubilant’s expertise in chemistry, biology and crystallography to offer a highly competitive

Regulatory approvals have also been obtained and dosing will begin shortly in two additional trials: a randomized Phase II study to evaluate NKTR-102 versus irinotecan in second-line colorectal

The CE-marked assay can identify patients infected with specific viral genotypes known to pose the highest risk for progression to cervical cancer, said Abbott. The new assay uses

The milestone payment of E2.5 million was triggered by enrolling the seventh patient in the multinational Fentanyl Taifun Phase III program in late December 2008. Enrollment is ongoing

The JZP-6 Phase III clinical trial program includes two randomized, double-blind, placebo-controlled studies. The first study was completed and positive top-line results were announced in November 2008. The

The agreement is Burnham’s first broad-based partnership with a large pharmaceutical company. Under this multi-year agreement, Burnham will provide Johnson & Johnson Pharmaceutical R&D (J&JPRD) with access to

The partnership between PRA Taiwan, the Taiwanese subsidiary of PRA International, Mediscience and LSK encompasses the joint management of multinational clinical trials in Asia as well as related

Schering-Plough will also collaborate with Symyx to develop within the Symyx Notebook a commercial metrology module built on the Symyx Lab Operational Informatics platform. The metrology module will

Viprinex was recently studied in a clinical trial to determine whether it was effective in improving patient outcome when given within six hours of a stroke, but the